Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Immunocore Holdings plc

Get SEC filing alerts via email and in your feed for Immunocore Holdings plc

IMCR

Immunocore Holdings plc

About Immunocore Holdings plc

Immunocore Holdings plc is a biotechnology company developing immunomodulating medicines using its proprietary ImmTAX platform. Its focus includes cancer, infectious diseases, and autoimmune conditions, with key products like KIMMTRAK for uveal melanoma. The company leverages engineered TCRs to create off-the-shelf bispecific therapeutics targeting intracellular and cell surface proteins, aiming to improve patient outcomes through innovative, targeted immunotherapies.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Immunocore Holdings plc

1
1
Immunocore Holdings plc Immunocore Holdings Reports $106.7 Million Revenue in Q1 2026, Driven by KIMMTRAK Sales

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Immunocore Holdings plc Immunocore Holdings Reports $400 Million Revenue for 2025, Net Loss Decreases

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
Immunocore Holdings plc Immunocore Reports 29.2% Revenue Growth in Q3 2025, Despite Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Immunocore Holdings plc Immunocore Reports 30% Revenue Growth to $97.964 Million in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Immunocore Holdings plc Immunocore Reports 33.2% Revenue Growth to $93.9 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Immunocore Holdings plc Immunocore Holdings plc Reports 23.7% Revenue Growth, Strong Cash Reserves in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments